PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Drug ReportsPhentermine
Phentermine
Adipex-p, Ionamin, Lomaira, Phentermine, Qsymia (phentermine) is a small molecule pharmaceutical. Phentermine was first approved as Fastin on 1982-01-01. It is used to treat obesity in the USA.
Download report
Favorite
Searched
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
nutritional and metabolic diseasesD009750
signs and symptoms pathological conditionsD013568
Trade Name
FDA
EMA
Adipex-p, Phentermine (discontinued: Adipex-p, Fastin, Ionamin, Obestin, Oby-trim, Phentermine, Phentermine resin complex, Suprenza, Tora, Wilpo)
Combinations
Phentermine topiramate, Qsymia
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Phentermine hydrochloride
Tradename
Company
Number
Date
Products
SUPRENZACitius PharmaceuticalsN-202088 DISCN2011-06-13
3 products
FASTINGSKN-017352 DISCN1982-01-01
1 products
WILPOSandozN-012737 DISCN1982-01-01
1 products, RLD
Hide discontinued
Phentermine hydrochloride
+
Topiramate
Tradename
Company
Number
Date
Products
QSYMIAVivusN-022580 RX2012-07-17
4 products, RLD, RS
Phentermine resin complex
Tradename
Company
Number
Date
Products
IONAMINUCBN-011613 DISCN1982-01-01
2 products
Hide discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
adipex-pANDA2024-09-03
lomairaANDA2025-07-21
phentermineANDA2025-04-24
phentermine and topiramateANDA2025-06-24
phentermine and topiramate extended-releaseANDA2025-05-21
phentermine hclANDA2024-10-15
phentermine hcl c-ivANDA2025-01-22
phentermine hcl c-iv phentermine hydrochlorideANDA2023-04-12
phentermine hydrochlorideANDA2025-07-23
qsymiaNew Drug Application2024-10-03
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
obesityEFO_0001073D009765E66.9
painEFO_0003843D010146R52
epilepsyEFO_0000474D004827G40.9
lennox gastaut syndrome—D065768G40.81
infantile spasmsEFO_1000643D013036G40.82
partial epilepsiesEFO_0004263D004828—
tonic-clonic epilepsyEFO_0007262D004830—
bipolar disorderEFO_0000289D001714F30.9
Agency Specific
FDA
EMA
Expiration
Code
PHENTERMINE HYDROCHLORIDE / TOPIRAMATE, QSYMIA, VIVUS
2025-06-24NPP
Patent Expiration
Patent
Expires
Flag
FDA Information
Phentermine Hydrochloride / Topiramate, Qsymia, Vivus
85802992029-06-14U-3399
85802982029-05-15DP
88950572028-06-09U-3398
88950582028-06-09DP
90119052028-06-09DP
90119062028-06-09U-3398
Phentermine Hydrochloride, Suprenza, Citius Pharms
84401702029-03-14DP
ATC Codes
A: Alimentary tract and metabolism drugs
— A08: Antiobesity preparations, excl. diet products
— A08A: Antiobesity preparations, excl. diet products
— A08AA: Centrally acting antiobesity products
— A08AA01: Phentermine
— A08AA51: Phentermine and topiramate
HCPCS
No data
Clinical
Clinical Trials
77 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
ObesityD009765EFO_0001073E66.92243—11
OverweightD050177—E66.3—1—3—4
Pediatric obesityD063766—————2—2
Blood pressureD001794EFO_0004325————1—1
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Type 2 diabetes mellitusD003924EFO_0001360E11—11——2
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Diabetes mellitusD003920EFO_0000400E08-E13—2———2
Obstructive sleep apneaD020181EFO_0003918G47.3311———1
Sleep apnea syndromesD012891EFO_0003877G47.311———1
ApneaD001049—R06.8111———1
Bariatric surgeryD050110———1———1
Weight lossD015431———1———1
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Renal insufficiencyD051437—N191————1
Liver diseasesD008107EFO_0001421K70-K771————1
Hepatic insufficiencyD048550——1————1
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common namePhentermine
INNphentermine
Description
Phentermine is a primary amine. It has a role as a dopaminergic agent, an adrenergic agent, a sympathomimetic agent, an appetite depressant, a central nervous system stimulant and a central nervous system drug. It is a conjugate base of a phentermine(1+).
Classification
Small molecule
Drug classAppetite suppressant
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
CC(C)(N)Cc1ccccc1
Identifiers
PDB—
CAS-ID122-09-8
RxCUI—
ChEMBL IDCHEMBL1574
ChEBI ID8080
PubChem CID4771
DrugBankDB00191
UNII IDC045TQL4WP (ChemIDplus, GSRS)
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
Qsymia – Vivus
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Estimated US medical usage
Phentermine
Total medical expenditures per year (USD, in millions)
Plot placeholder
Mock data
Subscribe for the real data
Number of persons purchased
Plot placeholder
Mock data
Subscribe for the real data
Number of purchases
Plot placeholder
Mock data
Subscribe for the real data
Refill frequency
Plot placeholder
Mock data
Subscribe for the real data
Price per prescription (USD)
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 3,383 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
6,574 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use